E
Eneida R. Nemecek
Researcher at Oregon Health & Science University
Publications - 98
Citations - 6044
Eneida R. Nemecek is an academic researcher from Oregon Health & Science University. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 23, co-authored 83 publications receiving 4125 citations. Previous affiliations of Eneida R. Nemecek include Fred Hutchinson Cancer Research Center & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Shannon L. Maude,Theodore W. Laetsch,Jochen Buechner,S. Rives,Michael Boyer,Henrique Bittencourt,Peter Bader,Michael R. Verneris,Heather E. Stefanski,G.D. Myers,Muna Qayed,B. De Moerloose,Hidefumi Hiramatsu,Krysta Schlis,Kara L. Davis,Paul L. Martin,Eneida R. Nemecek,Gregory A. Yanik,Christina Peters,André Baruchel,Nicolas Boissel,Francoise Mechinaud,Adriana Balduzzi,Joerg Krueger,Carl H. June,Bruce L. Levine,Patricia A. Wood,Tanya Taran,Mimi Leung,Karen Thudium Mueller,Yiyun Zhang,Kapildeb Sen,David Lebwohl,Michael A. Pulsipher,Stephan A. Grupp +34 more
TL;DR: In this global study of CAR T‐cell therapy, a single infusion of tisagenlecleucel provided durable remission with long‐term persistence in pediatric and young adult patients with relapsed or refractory B‐cell ALL, with transient high‐grade toxic effects.
Journal ArticleDOI
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
Elena Orlando,Xia Han,Catherine Tribouley,Patricia A. Wood,Rebecca Leary,Markus Riester,John E. Levine,Muna Qayed,Stephan A. Grupp,Michael Boyer,Barbara De Moerloose,Eneida R. Nemecek,Henrique Bittencourt,Hidefumi Hiramatsu,Jochen Buechner,Stella M. Davies,Michael R. Verneris,Kevin Nguyen,Jennifer Brogdon,Hans Bitter,Michael Morrissey,Piotr Pierog,Serafino Pantano,Jeffrey A. Engelman,Wendy Winckler +24 more
TL;DR: Mutations in the CD19 gene suggesting irreversible loss of its surface expression are identified in the majority of analyzed cases of CD19– relapse in two clinical trials of pediatric ALL CD19 CAR T therapy, offering considerations for the rational choice of follow-up therapies.
Journal ArticleDOI
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure
Paul G. Richardson,Marcie L. Riches,Nancy A. Kernan,Joel A. Brochstein,Shin Mineishi,Amanda M. Termuhlen,Sally Arai,Stephan A. Grupp,Eva C. Guinan,Paul L. Martin,Gideon Steinbach,Amrita Krishnan,Eneida R. Nemecek,Sergio Giralt,Tulio E. Rodriguez,Reggie E. Duerst,John Doyle,Joseph H. Antin,Angela R. Smith,Leslie Lehmann,Richard E. Champlin,Alfred P. Gillio,Rajinder P.S. Bajwa,Ralph B. D'Agostino,Joseph M. Massaro,Diane Warren,Maja Miloslavsky,Robin Hume,Massimo Iacobelli,Bijan Nejadnik,Alison L. Hannah,Robert J. Soiffer +31 more
TL;DR: Defibrotide was associated with significant improvement in day +100 survival and CR rate and the historical-control methodology offers a novel, meaningful approach for phase 3 evaluation of orphan diseases associated with high mortality.
Journal ArticleDOI
The genomic landscape of juvenile myelomonocytic leukemia.
Elliot Stieglitz,Amaro Taylor-Weiner,Tiffany Y. Chang,Laura C. Gelston,Yong Dong Wang,Tali Mazor,Emilio Esquivel,Ariel Yu,Sara Seepo,Scott R. Olsen,Mara Rosenberg,Sophie Archambeault,Ghada Abusin,Kyle Beckman,Patrick A. Brown,Michael Briones,Benjamin Carcamo,Todd Cooper,Gary V. Dahl,Peter D. Emanuel,Mark Fluchel,Rakesh K. Goyal,Robert J. Hayashi,Johann Hitzler,Christopher Hugge,Y. Lucy Liu,Yoav Messinger,Donald H. Mahoney,Philip M. Monteleone,Eneida R. Nemecek,Philip A. Roehrs,Reuven J. Schore,Kimo C. Stine,Clifford M. Takemoto,Jeffrey A. Toretsky,Joseph F. Costello,Adam B. Olshen,Chip Stewart,Yongjin Li,Jing Ma,Robert B. Gerbing,Todd A. Alonzo,Gad Getz,Gad Getz,Tanja A. Gruber,Todd R. Golub,Todd R. Golub,Kimberly Stegmaier,Kimberly Stegmaier,Mignon L. Loh +49 more
TL;DR: Genomically characterize serial samples from patients at diagnosis through relapse and transformation to acute myeloid leukemia to expand knowledge of the mutational spectrum in JMML and identified recurrent mutations in genes involved in signal transduction, splicing, Polycomb repressive complex 2 (PRC2) and transcription.
Journal ArticleDOI
Allogeneic Human Mesenchymal Stem Cell Therapy (Remestemcel-L, Prochymal) as a Rescue Agent for Severe Refractory Acute Graft-versus-Host Disease in Pediatric Patients
Joanne Kurtzberg,Susan E. Prockop,Pierre Teira,Henrique Bittencourt,Victor Lewis,Ka Wah Chan,Biljana Horn,Lolie Yu,Julie-An Talano,Eneida R. Nemecek,Charles R. Mills,Sonali Chaudhury +11 more
TL;DR: The risk/benefit profile of remestemcel-L (Prochymal), a third-party, off-the-shelf source of hMSCs, as a rescue agent for treatment-resistant aGVHD in pediatric patients is evaluated.